Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

• Izumi, Kouji

• Itai, Shingo

• Takahashi, Yoshiko

• Maolake, Aerken

• Namiki, Mikio

抄録

Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that demonstrate optimal efficacy against this type of HT. The charts of 50 cases of patients that had received VEGFR-TKI treatment were retrospectively examined. The association between patient background and TKI-induced HT, and the effect of administering AHTA were analyzed. High systolic blood pressure at baseline was identified to be a predictive factor for HT. In addition, there was no difference observed between calcium channel blockers (CCBs) and angiotensin receptor II blockers (ARBs) as first-line AHTA for the control of HT. The findings of the present study may aid with predicting the onset of TKI-induced HT, as well as for its management via the primary use of either CCBs or ARBs.

収録刊行物

• Oncology Letters

  Oncology Letters 8 (1), 305-308, 2014-09-01

  Spandidos Publications

キーワード

• Hypertension
• Kidney cancer
• Tyrosine kinase inhibitor

詳細情報

• CRID: 1050282810927759744
• NII論文ID: 120005463333
• ISSN: 17921082
• Web Site: http://hdl.handle.net/2297/39036
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles